[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hangzhou Sumgen Biotech Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":110},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,65,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100627388","phase-2-to-evaluate-the-efficacy-and-safety-of-sg301-sc-injection-in-systemic-lupus-erythematosus-100627388",false,"NCT07447986","To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus","A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study to Evaluate the Efficacy and Safety of SG301 SC Injection in Patients With Systemic Lupus Erythematosus","Inclusion Criteria:\n\n1. Voluntarily participate in the clinical study and sign a written informed consent form.\n2. Participants must be diagnosed with SLE in accordance with the 2019 European League Against Rheumatism (EULAR)\u002FAmerican College of Rheumatism (ACR) SLE classification criteria and have inadequate response to standard treatment, intolerance to standard treatment, or recurrent disease.\n3. SLEDAI-2K score ≥ 8 points, with clinical features corresponding to a SLEDAI-2K score ≥ 4 points.\n4. Positive serological test results for autoantibodies, defined as antinuclear antibody (ANA) positivity and\u002For anti-double-stranded DNA (anti-dsDNA) antibody positivity.\n5. Body weight ≥ 35 kg.\n6. Must have received standard treatment for at least 8 weeks before the first dose and maintained a stable dose of the treatment unchanged for at least 4 weeks before the first dose.\n7. Participants of childbearing potential or whose partners are of childbearing potential must agree to use effective contraceptive measures throughout the entire study period and within 6 months after the last dose.\n\nExclusion Criteria:\n\n1. Previous use of CD38 or monoclonal antibodies targeting CD38.\n2. Active central nervous system (CNS) disease within 2 months before the first dose, or CNS disease that the investigator believes may require treatment with prohibited therapies specified in the protocol.\n3. Diagnosis of mixed connective tissue disease or a history of any overlap syndrome between SLE and systemic sclerosis.\n4. Laboratory abnormalities.\n5. Current acute or chronic infection meeting any of the following criteria.\n6. Participation in any other clinical trial within 4 weeks before the first dose (excluding participants who provided informed consent but did not receive trial treatment, or only received placebo).\n7. Use of any targeted T or B lymphocyte drugs (e.g., rituximab) within 3 months before the first dose.\n8. Receipt of any B cell-depleting drugs (such as belimumab, telitacicept) within 4 weeks or 5 half-lives (whichever is shorter) before the first dose.\n9. Receipt of JAK inhibitor treatment within 2 weeks before the first dose.\n10. Presence of severe cardiovascular and cerebrovascular diseases.\n11. Mycobacterium tuberculosis infection.\n12. Presence of HIV infection, active hepatitis B, or hepatitis C.\n13. Known history of active syphilis.\n14. History of major organ transplantation (e.g., heart, lung, kidney, liver) or hematopoietic stem cell\u002For bone marrow transplantation.\n15. Other conditions that the investigator believes would prevent the participant from participating in the study.","ALL","18 Years","70 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This was a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study. The primary objective was to evaluate the efficacy of SG301 SC injection in participants with Systemic Lupus Erythematosus (SLE) based on the Systemic Lupus Erythematosus Responder Index -4 (SRI-4) response rate. The secondary objectives were to assess the safety, pharmacokinetics, pharmacodynamics, and immunogenicity profiles of SG301 SC injection in these participants .",[27],"Systemic Lupus Erythematosus (SLE)","RECRUITING","2026-04-01",{"date":31,"type":32},"2026-04-02","ACTUAL",{"date":34,"type":32},"2026-03-26",{"date":36,"type":21},"2027-12-31",{"name":38,"class":39},"Hangzhou Sumgen Biotech Co., Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":5},"100627865","phase-1-to-evaluate-the-safety-of-sg2918-in-patients-with-relapsedrefractory-multiple-myeloma-100627865","NCT07454187","To Evaluate the Safety of SG2918 in Patients With Relapsed\u002FRefractory Multiple Myeloma","A Phase 1b\u002F2 Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG2918 for Injection in Patients With Relapsed\u002FRefractory Multiple Myeloma","Inclusion Criteria:\n\n1. Age ≥ 18 years and ≤ 80 years.\n2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.\n3. Life expectancy ≥ 3 months.\n4. Documented diagnosis of multiple myeloma.\n5. Measurable disease at screening (per IMWG criteria).\n6. Relevant laboratory values obtained within 7 days prior to the first dose must meet protocol-specified thresholds.\n7. Resolution of adverse events related to prior antineoplastic therapy to Grade ≤ 1 or baseline (CTCAE v6.0).\n8. Female participants of childbearing potential and male participants whose partners are of childbearing potential must use at least one acceptable method of contraception during study treatment and for at least 7 months after the last dose.\n9. Male participants must refrain from sperm donation from the signing of the Informed Consent Form (ICF) until at least 7 months after the last study dose.\n\nExclusion Criteria:\n\n1. Patients with primary refractory multiple myeloma.\n2. Presence of non-bone-related extramedullary soft tissue plasmacytoma at screening.\n3. known meningeal or Central Nervous System involvement of multiple myeloma, or high suspicion of unconfirmed meningeal or Central Nervous System involvement.\n4. History of peripheral neuropathy of Grade ≥ 2.\n5. Active infection requiring systemic therapy within 2 weeks prior to the first dose.\n6. Hypertension that was not effectively controlled by standardized antihypertensive treatment within 2 weeks prior to the first dose, as judged by the investigator\n7. History of hypertensive crisis or hypertensive encephalopathy.\n8. Poorly controlled diabetes mellitus.\n9. Severe cardiovascular or cerebrovascular disease within 6 months prior to the first dose.\n10. Active hepatitis B or hepatitis C infection.\n11. Known history of active tuberculosis or active syphilis.\n12. Known hypersensitivity to any component of the investigational product.\n13. history of Grade 3-4 allergic reaction or life threatening hypersensitivity to any biological product.\n14. Received any of the following therapies or surgeries.\n\n    1. Prior treatment with LILRB4 targeted therapy; or severe adverse reaction to prior MMAE containing therapy.\n    2. Immunotherapy, macromolecular targeted therapy, or other antineoplastic biologic therapy within 28 days prior to the first dose.\n    3. Cytotoxic chemotherapy or small molecule therapy within 14 days prior to the first dose.\n    4. Modernized traditional Chinese herbal medicine with approved antineoplastic indications within 7 days prior to the first dose.\n15. Requirement for systemic corticosteroids (equivalent to \\> 10 mg prednisone per day) or other immunosuppressive agents within 14 days prior to the first dose or during the study.\n16. Administration of any live or live attenuated vaccine within 28 days prior to the first dose.\n17. Administration of other vaccines (e.g., inactivated COVID-19 vaccine) within 14 days prior to the first dose.\n18. Immune related toxicity during prior antineoplastic immunotherapy that resulted in permanent treatment discontinuation.\n19. Current or previous idiopathic pulmonary fibrosis or idiopathic pneumonia;\n20. Current acute pulmonary disease, interstitial lung disease, or pneumonia.\n21. Any other malignancy diagnosed within 5 years prior to the first dose.\n22. Documented history of neurological or psychiatric disorder.\n23. Any other condition that, in the opinion of the investigator, may render the participant unsuitable for study participation.","80 Years",{"count":50,"type":21},40,[52,24],"PHASE1","The primary objective of this study was to evaluate the safety and tolerability of SG2918 in patients with relapsed\u002Frefractory multiple myeloma.",[55],"Relapsed\u002FRefractory Multiple Myeloma","NOT_YET_RECRUITING","2026-03-03",{"date":59,"type":32},"2026-03-06",{"date":61,"type":21},"2026-03-14",{"date":63,"type":21},"2028-12-31",{"name":38,"class":39},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100555199","phase-3-a-clinical-study-comparing-sg301-plus-pomalidomide-and-dexamethasone-to-placebo-plus-pomalidomide-and-dexamethasone-in-relapsed-or-refractory-multiple-myeloma-patients-100555199","NCT06508983","A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients","A Phase 3 Randomized, Placebo-controlled, Double-blind, Multicenter Study Comparing SG301 in Combination With Pomalidomide and Dexamethasone Versus Placebo in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","Inclusion Criteria:\n\n1. Understand and voluntarily sign the informed consent form (ICF).\n2. Males and females aged 18-75 years (inclusive)\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2\n4. Expected survival time of ≥3 months.\n5. Subjects had a documented diagnosis of multiple myeloma with evidence of measurable disease.\n6. Subjects had received at least 1 prior lines of anti-myeloma therapy, which must include lenalidomide and a proteasome inhibitor (bortezomib, carfilzomib or ixazomib) given alone or in combination.\n7. Subjects must have documented evidence of PD on or after the last regimen.\n8. Adequate function of vital organs\n9. Women of childbearing potential (WOCBP) must agree to follow instructions for methods of contraception for 4 weeks before the start of study treatment, for the duration of study treatment, and for 6 months after cessation of SG301 or 4 weeks after cessation of pomalidomide, whichever is longer. WOCBP must have 2 negative serum or urine pregnancy tests, one 10-14 days prior to start of study treatment and one 24 hours prior to the start of study treatment.\n\nExclusion Criteria:\n\n1. Primary refractory multiple myeloma defined as participants who had never achieved at least a minimal response (MR) with any treatment during the disease course.\n2. Bone independent extramedullary disease at screening.\n3. Subjects who are primary refractory to a prior CD38 monoclonal antibody therapy.\n4. Previous exposure to pomalidomide.\n5. Subject has received chemotherapy or small molecule antitumor therapy within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is shorter, before the first dose of study treatment;\n6. Subject has received tumor biotherapy within 4 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is shorter, before the first dose of study treatment;\n7. Subject has received investigational agents within 4 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is shorter (but not less than 14 days), before the first dose of study treatment;\n8. Active hepatitis B, or C.\n9. Known HIV infection.\n10. Known active tuberculosis or positive treponema pallidum antibodies.\n11. Subjects with clinical significant organ dysfunction that does not meet the study needs.\n12. Previous allogenic stem cell transplant or autologous stem cell transplantation (ASCT) before the first dose of study treatment.\n13. Known allergy to any component of the investigational medicinal product.\n14. Any concurrent medical or psychiatric condition or disease (eg, active systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary disease) that is likely to interfere with the study procedures or results or that, in the opinion of the investigator, would constitute a hazard for participating in this study.","75 Years",{"count":74,"type":21},360,[76],"PHASE3","The purpose of this study is to evaluate the effects of the addition of SG301 injection to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.",[55],"2025-06-24",{"date":81,"type":32},"2025-06-27",{"date":83,"type":32},"2024-06-14",{"date":85,"type":21},"2028-03-31",{"name":38,"class":39},12,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},"100505129","phase-1-sg1906-for-cldn182-positive-solid-tumors-100505129","NCT05857332","SG1906 for CLDN18.2-Positive Solid Tumors","A Phase Ia\u002FIb Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.","CSG-1906-101","Inclusion Criteria:\n\n* Patients must meet all the following criteria to be eligible for participation in this study:\n\n  1. Understand and voluntarily sign the informed consent form (ICF).\n  2. Age ≥18 years.\n  3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.\n  4. Expected survival time of ≥3 months.\n  5. Able to provide tumor tissue samples for CLDN18.2 detection.\n  6. Specific requirements for patients enrolled in Phase Ia and Phase Ib are as follows:\n\n     Phase Ia Dose Escalation Phase\n     1. Patients with CLDN18.2-positive histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor who have relapsed after standard therapy, have failed standard therapy, are intolerant to standard therapy, are not eligible for standard therapy, or refuse standard therapy.\n     2. CLDN18.2 positivity is defined as H score ≥1 by central laboratory immunohistochemistry.\n\n     Phase Ib Dose Expansion Stage\n     1. Patients with histologically or cytologically confirmed CLDN18.2-positive locally advanced unresectable or metastatic G\u002FGEJ adenocarcinoma or pancreatic cancer who have failed to respond to standard therapy, have relapsed after standard therapy, or are intolerant to standard therapy.\n     2. CLDN18.2 positivity is defined as H score ≥40 by central laboratory immunohistochemistry.\n  7. At least one evaluable lesion (refer to Response Evaluation Criteria in Solid Tumors, version 1.1 \\[RECIST 1.1\\]).\n  8. Adequate function of vital organs, defined as follows:\n\n     1. Bone marrow function (no transfusion, erythropoietin, granulocyte colony-stimulating factor, or other medically supportive therapy within 7 days prior to the first dose): neutrophil count ≥1.5 × 109\u002FL, platelet count ≥100 × 109\u002FL, and hemoglobin level ≥10.0 g\u002FdL.\n     2. Adequate liver function, which must meet all of the following criteria:\n\n        * Serum total bilirubin ≤1.5 × upper limit of normal (ULN).\n        * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (AST and ALT ≤5 × ULN in patients with liver metastases).\n        * Albumin ≥3.0 g\u002FL.\n     3. Renal function: serum creatinine ≤1.5 × ULN or endogenous creatinine clearance ≥50 mL\u002Fmin (Cockcroft-Gault formula).\n     4. Coagulation: international normalized ratio ≤1.5 × ULN or prothrombin time ≤1.5 × ULN, activated partial thromboplastin time ≤1.5 × ULN without receiving anticoagulation therapy.\n  9. Toxicity caused by prior anti-tumor therapy recovered to Grade 0 to 1 (CTCAE 5.0), except for alopecia, Grade ≤2 sensory neuropathy, lymphocytopenia, and endocrine disorders controlled with hormone replacement therapy.\n  10. Female patients of childbearing potential and male patients whose female partners are of childbearing potential need to use at least one approved contraceptive (e.g., intrauterine device, pill, or condom) during study treatment and for at least 6 months (180 days) after the last dose; female patients of childbearing potential must have a negative blood human chorionic gonadotropin (HCG) test within 7 days prior to dosing and must not be lactating.\n  11. Male patients must refrain from donating sperm from the time the ICF is signed until at least 6 months after the last dose.\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria cannot be enrolled:\n\n1. Presence of active central nervous system metastatic lesions; presence of metastases to the brainstem or meninges, spinal cord metastases or compression. Exception: patients with previously treated brain metastases (e.g., surgery, radiation therapy) who are clinically stable for at least 4 weeks after treatment (calculated from the first dose of investigational drug) and have discontinued corticosteroids for ≥14 days prior to the administration of investigational drug; patients with untreated, asymptomatic brain metastases (i.e., no neurological symptoms, no need for corticosteroids, brain metastases ≤1.5 cm in length, no significant edema around the brain metastases).\n2. Active autoimmune disease requiring systemic therapy within the past 2 years (e.g., use of immunomodulatory drugs, corticosteroids, or immunosuppressive medications); related replacement therapy is allowed (e.g., thyroid hormone, insulin, or physiologic corticosteroid replacement for renal or pituitary insufficiency).\n3. Pyloric obstruction or any other condition that can cause long-term chronic nausea, persistent recurrent vomiting (≥3 vomit episodes in 24 hours) or diarrhea.\n4. Patients who have recently developed gastrointestinal bleeding (i.e., a history of hematemesis, hematochezia, or melena within the past 3 months) without evidence of recovery confirmed by endoscopy or colonoscopy; or patients with evidence of risk of gastric bleeding.\n5. Patients with active gastrointestinal disease including, but not limited to, gastric or duodenal ulcers, acute gastric or intestinal perforation, acute necrotizing pancreatitis, ulcerative enteritis, congenital megacolon or Crohn's disease.\n6. Patients requiring long-term treatment with non-steroidal anti-inflammatory drugs (NSAIDs); patients who are using anticoagulants such as heparin at therapeutic doses or vitamin K antagonists (except for prophylaxis).\n7. Presence of body fluid (hydrothorax, ascites, pericardial effusion, etc.) requiring local treatment or repeated drainage.\n8. Unintentional weight loss ≥5% within 1 month prior to initial dose, even with peripheral or central intravenous nutritional support.\n9. History of hemolytic anemia from any cause (including Evans syndrome).\n10. History of defects in red blood cell production, hemoglobin production, or metabolism, such as glucose-6-phosphate dehydrogenase deficiency, thalassemia, sickle cell disease, and hereditary spherocytosis.\n11. History of hemophagocytic lymphohistiocytosis.\n12. Presence of active infection requiring antibiotic therapy within 2 weeks prior to the first dose, except for prophylaxis.\n13. Presence of cardiovascular system disease within 6 months prior to screening that meets any of the following:\n\n    1. Cardiac function: congestive heart failure of New York Heart Association (NYHA) class III or IV; left ventricular ejection fraction \\\u003C50%.\n    2. Clinically significant cardiac disease or surgery within 6 months prior to the first dose of the investigational drug, including myocardial infarction, unstable angina pectoris, cerebrovascular accident, coronary\u002Fperipheral artery bypass, etc.\n    3. QTcF (corrected QT interval with Fridericia formula) \\>450 ms in men and \\>470 ms in women; history of clinically significant ventricular arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, tip-twist ventricular tachycardia); history or family history of congenital long QT syndrome; arrhythmias requiring antiarrhythmic drug therapy (patients with atrial fibrillation with controllable heart rate 1 month prior to the first dose of the investigational drug may be enrolled).\n    4. History of arterial thrombosis, deep venous thrombosis and pulmonary embolism within 6 months prior to the first dose.\n14. Hypertension (systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure ≥90 mmHg) that has not been effectively controlled after treatment with standardized antihypertensive medication.\n15. Patients with active hepatitis B or C. In case of positive hepatitis B surface antigen (HBsAg) or positive hepatitis B core antibody (HBcAb) during the screening period, further hepatitis B virus (HBV) DNA titer testing must be performed (HBV DNA≤200 IU\u002FmL is required). Patients who are positive for hepatitis C virus (HCV) must receive further HCV RNA testing (no higher than the upper limit of the detection value at their study site); patients may be enrolled in the study only after active hepatitis B or C requiring treatment has been excluded.\n16. Known history of human immunodeficiency virus (HIV) infection (i.e., HIV antibody positive);\n17. Known history of Grade 3 to 4 hypersensitivity reactions to any biological product, history of life threatening hypersensitivity reactions, or known hypersensitivity to components of SG1906 drug product (Grade ≥3 hypersensitivity reactions).\n18. Have received any of the following treatments or procedures:\n\n    1. Prior treatment with any antitumor therapy targeting CLDN18.2 or CD47\n    2. Patients who have undergone open surgery ≤3 months prior to the first dose (except for surgeries for the purpose of biopsy).\n    3. Prior allogeneic organ grafting.\n    4. Systemic anticancer therapy (including chemotherapy, targeted therapy, hormonal therapy and immunotherapy) within 28 days or 5 drug half-lives (whichever is shorter) prior to the first dose of the investigational drug, and all AEs have not returned to grade ≤1 (CTCAE 5.0), except for alopecia.\n    5. Radiotherapy ≤14 days prior to the first dose of the investigational drug; palliative radiotherapy is allowed if it is completed within 2 weeks prior to the enrollment in the study and radiotherapy-related toxicity has recovered to grade ≤1 (CTCAE 5.0), except for alopecia\n    6. Any live vaccine within 4 weeks prior to the first dose of the investigational drug\n    7. Have received treatment with various growth factors, blood transfusions or other blood products for anemia or decreased platelet count within 14 days prior to the first dose of the investigational drug.\n19. Have received systemic corticosteroids (at a dose equivalent to \\>10 mg\u002Fday prednisone) or other immunosuppressive drugs within 14 days prior to the first dose. The following are permitted:\n\n    1. Topical or inhaled glucocorticoids in physiologic replacement doses are allowed\n    2. The use of short-course (≤7 days) corticosteroids at physiologic replacement doses for the prevention or treatment of non-autoimmune diseases is allowed.\n20. Any other condition that, in the opinion of the Investigator, may lead to inappropriate participation in this study.",{"count":97,"type":21},60,[52],"This is a Phase Ia\u002FIb Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients with CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.",[101],"Locally Advanced Unresectable or Metastatic Solid Tumors",{"date":103,"type":32},"2025-06-25",{"date":105,"type":32},"2023-05-30",{"date":107,"type":21},"2027-08-30",{"name":38,"class":39},9,""]